The presence of mutations in BRCA1 or BRCA2 genes are 20-fold higher in women with precocious breast cancer diagnosed before age 40.
Mutations in BRCA1 and BRCA2 account for approximately 5% of all breast cancers and between 10-15% of ovarian cancers.
Oncodona test offers genetic counselling by experts
Oncodona analyzes a panel of 21 genes.
It is the most advanced genetic test for early identification of predisposition to inherited cancer. Oncodona uses Next Generation Sequencing (NGS) to analyze genetic information present in a panel of 21 genes, including BRCA1 and BRCA2 genes, in order to locate harmful mutations.
Oncodona is a simple and complete test for all women who want to have the maximum information about their personal risk of developing cancer.